Shares of

Sepracor

( SEPR) were among the best-performing health-related stocks Tuesday, climbing 15% after the pharmaceutical company posted better-than-expected fourth-quarter results and gave a solid 2006 guidance.

For the fourth quarter, the company earned $37.2 million, or 32 cents a share, on sales of $311.1 million. Analysts polled by Thomson First Call expected earnings of 5 cents a share on sales of $282.9 million. A year earlier, Sepracor recorded a loss of $33.7 million, or 33 cents a share, on sales of $131.4 million.

Sepracor predicts 2006 earnings of $1.50 a share, above analysts' projection of $1.21 a share. The company sees sales of $1.28 billion. Analysts expect sales of $1.2 billion. Shares were up $7.24 to $55.62.

ICU Medical

(ICUI) - Get Report

tumbled 10% after the medical device maker posted mixed fourth-quarter financial results. The company earned $5.3 million, or 35 cents a share, on sales of $43.2 million. The earnings beat analysts' forecast for a profit of 30 cents a share, but Wall Street targeted higher sales of $45 million. For the year-earlier quarter, the company posted a loss of $1.5 million, or 11 cents a share, on sales of $15.2 million. ICU Medical shares recently were down $3.95 to $36.05.

Shares of

Universal Health Services

(UHS) - Get Report

fell 1% after the hospital operator's fourth-quarter earnings estimate and 2006 guidance fell below analyst expectations. The company expects to earn 16 cents to 18 cents a share on sales of about $967 million. Excluding items, the company sees earnings of 43 cents to 45 cents a share. Analysts project earnings of 56 cents a share and sales of $975.2 million. For all of 2005, Universal Health expects to report earnings of $1.90 to $1.92 a share and sales of about $3.93 billion. Without charges and other one-time items, the company sees 2005 earnings of $2.55 to $2.57 a share. Analysts project earnings of $2.62 a share on sales of $4 billion.

For 2006, Universal Health expects earnings of $2.70 to $2.75 a share, excluding stock-based compensation costs. Analysts project earnings of $2.85 a share. Shares were trading at $47.27, down 33 cents.

Wyeth

( WYE) fell 3% after the drugmaker posted fourth-quarter results that were below Wall Street expectations. The company earned $731.7 million, or 54 cents a share. Excluding items, the company earned $805.4 million, or 59 cents a share. Analysts expected earnings of 60 cents a share, before items. Wyeth posted sales of $4.75 billion, shy of analysts' target of $4.9 billion. In the year-earlier quarter, the company earned $860.7 million, or 64 cents a share, before items, while sales were $4.65 billion.

Wyeth continues to project 2006 adjusted earnings of $2.97 to $3.07 a share. The forecast includes stock-based compensation costs of 12 cents to 15 cents a share. Analysts project earnings of $3.04 a share, excluding stock-based compensation costs. Shares were down $1.25 to $46.68.

Shares of

Haemonetics

(HAE) - Get Report

jumped 15% after the blood processing company posted better-than-expected third-quarter earnings and boosted its fiscal-year earnings guidance. In the December quarter, the company earned $28.1 million, or $1.02 a share, including a one-time gain of 61 cents a share and a one-time charge of 9 cents a share. Without those items, the company would have earned 50 cents a share during the quarter, better than analysts' estimate of 45 cents a share. The company posted sales of $105.7 million, below Wall Street's target of $107.4 million. During the year-ago quarter, the company earned $11 million, or 42 cents a share, on sales of $98.1 million.

For the fiscal year, Haemonetics now expects earnings of $2.44 to $2.51 a share, up from an earlier view of $2.34 to $2.44 a share. The forecast includes one-time items. Analysts project earnings of $1.81 a share, excluding the one-time gain of 61 cents a share recorded during the third quarter. Haemonetics now sees 2006 sales growth of 8% to 10%, down from its previous guidance of 11% to 13%. The company attributed the lowered sales projection to its decision to shift to direct sales of its OrthoPAT product, rather than a distribution agreement. Shares were trading up $6.84 to $51.20.

Other health care volume movers included

Pfizer

(PFE) - Get Report

, down 12 cents to $25.82;

Boston Scientific

(BSX) - Get Report

, up 60 cents to $21.50;

Elan

(ELN)

, up 81 cents to $15.46;

Johnson & Johnson

(JNJ) - Get Report

, down 73 cents to $57.67;

Merck

(MRK) - Get Report

, up 11 cents to $34.57;

Acadia Pharmaceuticals

(ACAD) - Get Report

, up $2.93 to $13.22;

Gilead Sciences

(GILD) - Get Report

, up $1.40 to $59.30;

Omnicare

(OCR)

, down 33 cents to $48.63;

Amgen

(AMGN) - Get Report

, up 27 cents to $72.59;

Genta

( GNTA), up 11 cents to $2.54;

Guidant

( GDT), up $1.04 to $73.30;

Bristol-Myers Squibb

(BMY) - Get Report

, down 2 cents to $22.81; and

Teva Pharmaceutical Industries

(TEVA) - Get Report

, up 33 cents to $42.60.